ABM Therapeutics begins phase 1 trial of BRAF inhibitor ABM-1310
ABM Therapeutics said that the first cancer patient has been enrolled and dosed with its lead candidate ABM-1310, a BRAF inhibitor, in a phase 1 ... Read More
Differences between Malignant Tumors and Benign Tumors
What are the Characteristics of Neoplasia? Neoplasia comprises of both malignant and benign tumors. What are the differences between Malignant Tumors and Benign Tumors? Benign ... Read More